Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
maveropepimut-S
- Development stage
- Phase 2
- Lead developer
- BioVaxys Technology Corporation
- Modality
- Recombinant Proteins and Enzymes, Peptides, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Maveropepimut-S is a subcutaneously administered peptide-based therapeutic cancer vaccine designed to activate T cells against tumors expressing the protein survivin. It consists of five survivin-derived peptides with different human leukocyte antigen (HLA) restrictions, a universal T helper peptide, and a polynucleotide adjuvant encapsulated in a lipid depot formulation (DPX platform). The vaccine stimulates survivin-specific killer T cells that infiltrate tumors and promote the destruction of cancer cells by disrupting their survival mechanisms. Maveropepimut-S has demonstrated robust and durable immune responses in clinical trials for various cancers, particularly ovarian cancer. The drug is being developed as an immunotherapy for hard-to-treat solid tumors and hematologic malignancies[1][2][3][4][5][6].
- Brand names
- MVP-S
- Other names
- maveropepimut SSurvivac
02
Targets
BIRC5 (Survivin)
Beyond the preview
Go deeper on maveropepimut-S.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on maveropepimut-S.